To summarize, a TFR2 attempt is a feasible strategy in selected patients with CML, with favorable outcomes associated with maintenance of MR4.5 within 3 months. This evidence concerns the gene TFR2 and chronic myelogenous leukemia, BCR-ABL1 positive.